Authors: Steven Rosen, M.D., John Barsa, M.D., Timothy Deer, M.D., Elmer Dunbar, M.D., Gopala Dwarakanath, M.D., Gurpreet Padda, M.D. and Richard Rauck, M.D.
Published: AAPM 1/19/09
Poster presents 12 month data on efficacy, as well as 18 month data on median daily dose by visit. Mean reduction in VAS at 12 months is 26.9%, baseline NRS reduction was 1.8, and reduction in ODI was 27.6%. Conclusions are that the new Prometra pump provides pain relief consistent with current medical practice. Greater than 61% of patients at 6 months and greater than 66% of patients at 12 months reported statistically significant improvements in pain and disability.
